Albert Labs is a publicly listed company (CSE) that uses Real-World Evidence (RWE) to accelerate the psychedelic drug development process.
Albert Labs
By using data from actual clinical practice, Albert Labs hopes to make their psilocybin derivative KRN-101 available for the treatment of end-of-life anxiety associated with cancer.
Albert Labs Inc announced it is raising up to C$4 million via a brokered private placement ahead of its anticipated RTO on the CSE.
“Albert Labs is a laboratory-based, clinical research and drug development enterprise focused on improving patient access to psychedelic-assisted therapies through accelerated regulatory approval pathways. The company’s core focus is treating patients with urgent and unmet needs; these are critical mental health indications, that are not being addressed by big pharma, beginning with cancer-related anxiety, through trials in the UK and Europe. Albert will be the first psychedelics company to use an accelerated pathway, known as Real-World Evidence (RWE) studies, to swiftly provide access to patients in need.“
Activities
B2C
Pharmaceutical
Drug Discovery
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Albert Labs secures psilocybin licence from Health Canada (Proactive Investors, 17 May 2022)Albert Labs Appoints Principal Investigator for Real World Evidence Study for KRN-101 (Yahoo Finance, 26 May 2022)